Key Highlights
- Aquestive Therapeutics shares rose 9.52% to close at $3.91 on November 13, 2026.
- The FDA accepted the Anaphylm resubmission with a goal date of March 16, 2027.
- Management reaffirmed 2026 Revenue guidance of $46 million to $50 million.
- Cash was $90.3 million at the end of the third quarter.
Aquestive Therapeutics (NASDAQ:AQST) finished Friday's session, November 13, 2026, at $3.91, a gain of 9.52%, placing it among the stronger performers on a day when the broader market tilted lower. The move stood out against a weak backdrop for growth-oriented names: the Nasdaq Composite fell 0.91% to 25,136.27, the S&P 500 slipped 0.40% to 7,561.67, while the Dow Jones Industrial Average edged up 0.10% to 52,347.55. The Russell 2000 small-cap index lost 0.31%.
Anaphylm Decision Dominates
The company published no press release, regulatory update or analyst action dated November 12 or 13. Its latest substantive news was the third-quarter 2026 report, covered in a November 4 Earnings analysis, more than a week before this session.
That third-quarter coverage provides useful context for why the stock remains closely watched. According to that analysis, the quarter itself fell short of expectations, but the results matter less than an upcoming regulatory event. The Food and Drug Administration accepted Aquestive's resubmission for Anaphylm, its epinephrine product candidate, as a Class 2 response with a goal date of March 16, 2027. For a company of Aquestive's size, a pending approval decision of that kind tends to dominate how investors value the shares, and it can draw speculative buying well ahead of the date itself.
Guidance and Cash Position
The same report said management reaffirmed full-year revenue guidance of $46 million to $50 million and an adjusted EBITDA loss of $30 million to $35 million. Aquestive also nudged its year-end cash expectation to "more than $70 million," from "approximately $70 million" previously, and reported cash of $90.3 million at quarter end. Funding runway is a recurring concern for development-stage and early-commercial drug companies.
The earnings analysis noted shares were around $3.88 at the time it was written, so Friday's closing level leaves the stock close to where it stood shortly after the earnings report. Friday's jump recovered ground lost in the intervening sessions rather than pushing the shares to a new level. That pattern is common among low-priced biotech stocks, which can swing sharply on modest Volume as traders position around known future events.
March 2027 Decision Frames the Story
The wider market environment on Friday offered a mixed setting for healthcare small caps. Selling was concentrated in technology and semiconductors, with AMD (NASDAQ:AMD), Broadcom (NASDAQ:AVGO) and Nvidia (NASDAQ:NVDA) all lower after Nvidia disclosed on Thursday that chief executive Jensen Huang had resigned, with chief financial officer Colette Kress stepping in as interim CEO. Most S&P 500 sectors still advanced as money rotated away from technology. On the macro front, October producer prices rose 0.3% month over month, below the 0.4% forecast, though the 6.5% annual increase was the largest since November 2022. The 10-year Treasury Yield sat near 5.13% early in the day, and futures markets priced a Federal Reserve rate increase in December as close to certain, a headwind for cash-burning companies that depend on capital markets.
For now, Aquestive's story centers on the March 2027 Anaphylm decision, its cash position and its ability to meet reaffirmed guidance.






Please wait processing your request...